<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04406597</url>
  </required_header>
  <id_info>
    <org_study_id>NTCS-LOC</org_study_id>
    <nct_id>NCT04406597</nct_id>
  </id_info>
  <brief_title>Safety, Effectiveness and Operability of Using the New Tissue Containment System During Laparoscopic Ovarian Cystectomy</brief_title>
  <official_title>Safety, Effectiveness and Operability of Using the New Tissue Containment System With Hard Pipes Which Can Assemble With Detachable Trocars Seamlessly for Tissue Removal During Laparoscopic Ovarian Cystectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China-Japan Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China-Japan Friendship Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to evaluate the safety, effectiveness and operability of performing
      in-bag cystectomy and morcellation with the new tissue containment system during laparoscopic
      ovarian cystectomy. Premenopausal women, aged 18-45 undergoing laparoscopic cystectomy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 10, 2020</start_date>
  <completion_date type="Anticipated">December 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 10, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The exposure rate</measure>
    <time_frame>End of study - approximately two years</time_frame>
    <description>• Exposure is defined as &quot;disruption of the device (using dye leak testing or water testing) or visible tissue dissemination&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The ovarian reserve function</measure>
    <time_frame>Three months after the surgery</time_frame>
    <description>The ovarian reserve function is reflected by the concentration of anti-mullerian hormone(AMH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean procedure time</measure>
    <time_frame>Within one week after the surgery</time_frame>
    <description>Mean procedure time will be measured by hour/minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated blood loss during operation</measure>
    <time_frame>Within one week after the surgery</time_frame>
    <description>Blood loss during operation will be measured by volume (mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Intra- or post-operative complications</measure>
    <time_frame>Three months after the surgery</time_frame>
    <description>Intra or post complications rate (e.g. urinary, intestinal or nerve injury)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The patients' life quality postoperative: questionaire</measure>
    <time_frame>Three months after the surgery</time_frame>
    <description>The patients' life quality will be measured by The World Health Organization's Quality of Life Questionnaire-Brief Version（WHOQOL-BREF).The maximum value is 120 and the minimum is 0. The higher score means a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Surgery Task Load Index</measure>
    <time_frame>Within one week after the surgery</time_frame>
    <description>The Surgery Task Load Index will be measured by questionaire. The maximum value is 120 and the minimum is 0. The higher score means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of failure during in-bag cystectomy procedure</measure>
    <time_frame>End of study - approximately two years</time_frame>
    <description>Failure is defined as the operator's inability to successfully insert and extract the device.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Ovary Neoplasm</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>the New Tissue Containment System group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Using the New Tissue Containment System during Laparoscopic Ovarian Cystectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Without any protection system during Laparoscopic Ovarian Cystectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>the New Tissue Containment System</intervention_name>
    <description>Laparoscopic Ovarian Cystectomy using the New Tissue Containment System</description>
    <arm_group_label>the New Tissue Containment System group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal woman patient age 18-45 years

          -  Women with regular period

          -  Women with ovarian neoplasm (size: 3-10cm)

          -  Laparoscopic surgery required

          -  Body mass index 18.5-27.9kg/m2

          -  Subject able to comprehend and give informed consent for participation in this study

          -  Signed informed consent form

        Exclusion Criteria:

          -  Patient is not considered suitable for a laparoscopic ovarian cystectomy procedure

          -  The ovaries and pelvic cavity are severely adhered, and the tumor ruptures when free

          -  Women with Polycystic ovary syndrome

          -  Baseline AMH less than 0.5ng / mL

          -  Known to have participated in any other clinical trials or hormone therapy within 3
             months

          -  Women during pregnancy and lactation

          -  Women in acute stage infection of reproductive system or other parts

          -  Women combined with severe central nervous system, cardiovascular system, liver and
             kidney, digestive tract, respiratory system, endocrine metabolism (thyroid disease,
             Cushing syndrome, hyperprolactinemia) and skeletal muscle system and mental disorders
             contraindicating laparoscopic surgery

          -  Women with known or suspected poor compliance who cannot complete the trial

          -  Those who can not sign the informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yao Wang, MD</last_name>
    <phone>8684206115</phone>
    <email>wangyaopumc@163.com</email>
  </overall_contact>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 18, 2020</study_first_submitted>
  <study_first_submitted_qc>May 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2020</study_first_posted>
  <last_update_submitted>May 24, 2020</last_update_submitted>
  <last_update_submitted_qc>May 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China-Japan Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Jing Liang</investigator_full_name>
    <investigator_title>Vice Director of Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

